Immix Biopharma Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, Immix Biopharma stock has a consensus rating of "Strong Buy" and an average price target of $19.75. The average 1-year stock price forecast is 100.92% higher than the current stock price, while the lowest is $14.5 (+47.51%) and the highest is $27 (+174.67%).

Price Target: $19.75 (+100.92%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$14.5	$19.75	$20	$27
Change	+47.51%	+100.92%	+103.46%	+174.67%

Analyst Ratings

The average analyst rating for Immix Biopharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	1	2	2	2	2	3
Buy	0	0	2	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	2	4	4	4	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Patrick Dolezal LifeSci Capital	LifeSci Capital	Buy Initiates $19	Buy	Initiates	$19	+93.29%	Jun 17, 2026
Graig Suvannavejh Mizuho Securities	Mizuho Securities	Buy Maintains $15	Buy	Maintains	$15	+52.59%	May 26, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $15 → $20	Buy	Reiterates	$15 → $20	+103.46%	May 22, 2026
Judah Frommer Morgan Stanley	Morgan Stanley	Buy Reiterates $20	Buy	Reiterates	$20	+103.46%	Mar 25, 2026
Reni Benjamin Citizens JMP	Citizens JMP	Buy Initiates $23	Buy	Initiates	$23	+133.98%	Mar 9, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

45.13M

EPS This Year

-0.69

from -0.89

EPS Next Year

-0.74

from -0.69

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-1.35M	-8.22M	-16.14M	-22.67M	-29.96M	-46.28M
Net Income	-24.38M	-8.23M	-15.43M	-21.61M	-29.44M	-43.17M
EPS	-	-	-	-	-0.89	-0.69
Free Cash Flow	-2.10M	-4.31M	-5.94M	-7.55M	-13.61M	-35.80M
No. Analysts	-	-	-	-	-	5

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-0.57
Avg	-0.69
Low	-0.87

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-